Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Scottsdale Scientific, Inc. (STDS) -- Ignore unavailable to you. Want to Upgrade?

To: scouser who wrote (90)	4/30/1999 3:48:00 PM
From: Jim Bishop	Read Replies (1) \| Respond to of 105

Subject: BEST OF BFN NEWSLETTER - STDS Files to Become Fully Reporting; GBDI Sets Date For Launch of Web Site Sender: bizfn-updates-owner@BizFN.com Reply-To: bizfn-updates-owner@BizFn.com ---------------------------------------- BEST OF BFN NEWSLETTER bizfn.com April 29, 1999 A Business Financial Network Publication ---------------------------------------- ---------------------------------------- TABLE OF CONTENTS 1) Scottsdale (STDS) 2) GBid.com (GBDI) 3) Disclaimer - Please Read ---------------------------------------- 1) Scottsdale ------------------------------------ Scottsdale Scientific, Inc. 7332 East Butherus Drive - Suite 101 Scottsdale, Arizona 85260 Phone (888) 607-5399 or (602) 948-7444 e-Mail: stds@primenet.com ------------------------------------ COMPANY PRESS RELEASE (BSNS WIRE) Scottsdale Scientific Files Form 10SB to Become a Fully Reporting Company Business Editors/Medical & Health Writers SCOTTSDALE, Ariz.--(BW HealthWire)--April 29, 1999--Scottsdale Scientific, Inc. (Symbol: STDS), through its wholly owned subsidiary Allergy Research Group, Inc., announced today that it has initiated the process to become a fully reporting company by filing its Form 10SB. Scottsdale Scientific has retained the services of Blume Law Firm of Phoenix, Arizona. Blume Law Firm has filed the Form 10SB with the Securities and Exchange Commission, on behalf of Scottsdale Scientific. This filing extends the Company's goal of continual upgrade of its status and visibility to shareholders and the public. Scottsdale Scientific, Inc., through its wholly owned subsidiary, Allergy Research Group, Inc. is an innovative leader in nutraceutical research and product formulation. Since 1979, the Company is noted for quality, hypoallergenic nutritional supplements and supplies products to approximately 6,000 physicians and health care practitioners worldwide. Allergy Research Group was the first in the U.S. to introduce numerous specialty products including melatonin, a neurohormone, germanium sesquioxide (a trace mineral), AntiOx(tm), a broad-spectrum antioxidant, Buffered Vitamin C and the Total Nutrient Concept. (Includes all in one, proprietary formulas, Total Immune(tm), Total Nerve(tm) and Total Heart(tm)) For additional information, visit our web site at www.nutricology.com Disclaimer: This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements, which are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks defined in this document and in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof. CONTACT: Scottsdale Scientific Inc., Scottsdale Wendy Miller-Appleyard, 888/607-5399 or 602/948-7444